CARDIOVASCULAR SAFETY AND EFFICACY OF CELECOXIB: FOCUS ON TREATMENT AND CARDIOSOMATIC REHABILITATION


N.P. Lyamina, E.S. Karpova

FSBEI HE “Saratov State Medical University n.a. V.I. Razumovsky” of RMH, Saratov
At present time, due to demographic aging of the population, the number of comorbid diseases significantly increases. The most frequent comorbid age-related diseases is the pathology of the cardiovascular and the locomotor systems. The problem of cardiovascular safety of specific cyclooxygenase-2 inhibitors for cardiosomatic patients is one of the most acute. Previously, the use of non-steroidal anti-inflammatory drugs in patients with coronary artery disease was associated with an increased risk of cardiovascular complications, which limited their use in medical rehabilitation practice in this category of patients. The results of the PRECISION study demonstrate the cardiac safety of selective cyclooxygenase-2 inhibitors, namely celecoxib, which can contribute to the success of treatment of comorbid diseases. Key words: comorbid

About the Autors


Corresponding author: N.P. Lyamina – MD, Prof., Deputy Director for Science SRI of Cardiology FSBEI HE «Saratov State Medical University n.a. V.I. Razumovsky» of RMH, Saratov; e-mail: lyana_n@mail.ru


Similar Articles


Бионика Медиа